PLC-γ2 pY759 Antibody, anti-human, REAfinity™
Synonyms: PLCG2, APLAID, FCAS3, PLC-IV, PLC-gamma-2
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
2 Citations
Clone:
REA341 | K86-689.37
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC, MC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for PLC-γ2 pY759 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
Vio B515
Description:
Ramos cells, overnight serum starved and either left unstimulated (left peak) or stimulated with 10 µg/mL anti-human IgM antibodies for 3 minutes, were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-PLC-γ2 pY759 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.
Intracellular flow cytometry applications
APC
PE
PE-Vio 770
Vio B515
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-105-023, 130-104-971
Description:
Ramos cells, overnight serum starved and either left unstimulated (left peak) or stimulated with 10 µg/mL anti-human IgM antibodies for 3 minutes, were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-PLC-γ2 pY759 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Mass cytometry applications
pure
Conjugate:
pure
Used products:
130-124-532
Extended validation for PLC-γ2 pY759 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA341
K86-689.37
high

Cells were incubated with an excess of purified unconjugated PLC-γ2 pY759 (REA341) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Specifications for PLC-γ2 pY759 Antibody, anti-human, REAfinity™
Overview

Clone REA341 recognizes the phosphoinositide phospholipase C-gamma-2 (PLC-γ2) antigen phosphorylated at tyrosine 759 (pY759). PLC-γ isoforms are mainly regulated through receptors with intrinsic tyrosine kinase activity (e.g. growth factor receptors) or receptors (such as B and T cell antigen receptors) that are linked to the activation of nonreceptor tyrosine kinases through a complex signaling network. The two isoforms of PLC-γ have distinct tissue distributions. Whereas PLC-γ1 is expressed ubiquitously, the pattern of expression of PLC-γ2 is characterized by high levels in cells of hematopoietic origin. PLC-γ2 is a transmembrane signaling enzyme that catalyzes the conversion of phosphatidyl inositol biphosphate to inositol triphosphate (IP3) and diacylglycerol (DAG) using calcium as a cofactor. It has been implicated in collagen-induced signal transduction in platelets and antigen-dependent signaling in B-lymphocytes. PLC-γ2 is regulated through activation of tyrosine kinase-linked receptors. Phosphorylation of PLC-γ2 at tyrosines 753 and 759 leads to activation of the enzyme. Homozygous disruption of PLC-γ2 results in functional and signaling disorders in a subset of cell types including B cells, platelets, and mast cells.

Additional information: Clone REA341 displays negligible binding to Fc receptors.

Alternative names

PLCG2, APLAID, FCAS3, PLC-IV, PLC-gamma-2

Detailed product information

Technical specifications

Clone
REA341
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
PLC-γ2 pY759
Molecular mass of antigen [kDa]
148
Distribution of antigen
stem cells, hematopoietic stem and progenitor cells
Entrez Gene ID
RRID
AB_2928801, AB_2928802, AB_2653224, AB_2653227, AB_2653225, AB_2653228, AB_2653223, AB_2653226, AB_2889731

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for PLC-γ2 pY759 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support